Advertisement

Product › Details
CAR T-cell technology (Chimeric Antigen Receptor T-Cell technology)
![]() |
Next higher product group | Chimeric Antigen Receptor technology (CAR technology) |
![]() |
Status | 2012-10-06 |
![]() |
Organisation | Novartis (Group) |
Original research | University of Pennsylvania (UPenn) | |
Record changed: 2024-11-26 |
Advertisement

More documents for CAR T-cell technology (Chimeric Antigen Receptor T-Cell technology)
- [1] Roche. (11/26/24). "Press Release: Roche Enters into a Definitive Agreement to Acquire Poseida Therapeutics, Including Cell Therapy Candidates and Related Platform technologies". Basel....
- [2] T-Curx GmbH. (2/9/24). "Press Release: T-Curx Extends Its Management Team with Marion Jung, PhD, as Its New Chief Operating Officer"....
- [3] Legend Biotech Corporation. (11/13/23). "Press Release: Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3". Somerset, NJ....
- [4] T-Curx GmbH. (10/6/22). "Press Release: T-Curx GmbH, a German CAR-T Cell Biotech Spin-Off from University of Würzburg, Appoints Ulf Grawunder as CEO". Würzburg....
- [5] Arsenal Biosciences, Inc.. (9/27/22). "Press Release: Arsenal Biosciences Announces Joint Discovery Collaboration with Genentech to Identify Features of Successful T-Cell Therapies for Oncology". South San Francisco, CA....
- [6] Poseida Therapeutics, Inc.. (8/3/22). "Press Release: Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies". San Diego, CA....
- [7] Galapagos N.V.. (6/21/22). "Press Release: Galapagos to Acquire CellPoint and AboundBio to Accelerate Access to Next-generation Cell Therapies". Mechelen, Leiden & Pittsburgh, PA....
- [8] Atara Biotherapeutics, Inc.. (5/19/22). "Press Release: Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer". South San Francisco, CA....
- [9] Kuur Therapeutics, Inc.. (5/4/21). "Press Release: Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform". Buffalo, NY....
- [10] Sirion Biotech GmbH. (1/7/21). "Press Release: Sirion Biotech GmbH Licensed Its LentiBoost Transduction Technology to Cellectis". Munich & Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top